Pediatrics

DSM-5 Diagnostic Criteria and Subtypes

ADHD is diagnosed based on a persistent pattern of inattention and/or hyperactivity-impulsivity more frequent/severe than typical for developmental level, with symptoms present before age 12, occurring across multiple settings (e.g., both home and school — distinguishing genuine ADHD from situational difficulties confined to a single setting), and causing clear functional impairment. Three presentations: Predominantly Inattentive, Predominantly Hyperactive-Impulsive, and Combined (both domains) — with symptom count thresholds (6+ symptoms from the relevant domain, for children under 17) required.

Differential Diagnosis

A broad differential given significant symptom overlap: normal developmental variation (age-appropriate activity mistaken for pathology, particularly in very young children), learning disabilities (Q80 — producing apparent inattention specifically in academic contexts), anxiety and mood disorders (inattention/restlessness), Autism Spectrum Disorder (frequently co-occurs, requiring recognition of comorbidity rather than either/or thinking), hearing impairment, sleep disorders (including obstructive sleep apnea — daytime inattention/hyperactivity), and psychosocial stressors/adverse childhood experiences.

Management

Behavioral therapy is recommended as a foundational, first-line intervention, particularly emphasized as the preferred initial approach for preschool-age children (given a more limited pharmacological evidence/safety base at this age and generally favorable behavioral response) — including parent training in behavior management and classroom-based interventions.

Pharmacological management, typically added for school-age children with persistent, functionally impairing symptoms despite behavioral intervention:

• Stimulant medications (methylphenidate, amphetamine-based formulations) — the most extensively evidence-supported, first-line option, available in immediate-release and multiple extended-release preparations for individualized duration matching
• Atomoxetine — a non-stimulant, selective norepinephrine reuptake inhibitor, an alternative particularly for households with substance misuse concern, significant tic disorder (stimulants can exacerbate), or stimulant side-effect intolerance — somewhat less robust efficacy and a delayed onset of effect (weeks) vs stimulants' rapid onset
• Alpha-2 agonists (guanfacine, clonidine, extended-release) — additional non-stimulant options, sometimes for prominent hyperactivity/impulsivity or as an adjunct
• Ongoing monitoring for growth (modest stimulant effect on growth velocity), cardiovascular parameters, and appetite/sleep effects is standard longitudinal management

The Four Developmental Domains

Gross Motor (large muscle movement/postural control), Fine Motor-Adaptive (hand function, manipulation, visual-motor coordination), Language (receptive and expressive), and Personal-Social (interaction with environment/people, including self-care).

Detailed Milestones by Age

Clinical Application

This structured, age-anchored framework underlies routine well-child developmental surveillance at each scheduled visit, providing the foundation both for identifying children requiring more formal developmental screening (Q75) and for recognizing specific delay patterns (isolated or global, Q67) warranting further etiological evaluation.

Definitions

Precocious puberty is generally defined as pubertal onset before age 8 in girls and before age 9 in boys (with some regional/population-specific variation reflecting secular trends toward earlier onset in some populations).

Central (Gonadotropin-Dependent) Precocious Puberty

Results from premature activation of the hypothalamic-pituitary-gonadal (HPG) axis, with premature, sustained pulsatile GnRH secretion driving pituitary LH/FSH release and gonadal sex steroid production — true, complete precocious puberty following the normal physiological sequence, simply occurring too early. Causes: idiopathic (most common, particularly in girls), CNS lesions (hypothalamic hamartoma — a classic association, brain tumors, hydrocephalus, prior CNS radiation/significant injury or infection), and other causes of early HPG axis activation.

Peripheral (Gonadotropin-Independent) Precocious Puberty

Results from excess sex steroid production/exposure independent of, and without activating, the HPG axis — gonadotropin (LH/FSH) levels remain suppressed/prepubertal despite clinical pubertal features. Causes: McCune-Albright syndrome (precocious puberty, café-au-lait macules with irregular “coast of Maine” border, and fibrous dysplasia of bone, from a somatic activating mutation), congenital adrenal hyperplasia (excess adrenal androgen), gonadal/adrenal tumors producing autonomous sex steroid secretion, and exogenous sex steroid exposure.

Diagnostic Workup — The GnRH Stimulation Test as the Central Distinguishing Tool

Following initial assessment (Tanner staging, growth velocity, bone age — both types typically cause advanced bone age from the growth-accelerating effect of sex steroids, though the ultimate untreated outcome is often reduced final adult height from premature epiphyseal fusion), the GnRH stimulation test distinguishes central from peripheral: exogenous GnRH (or agonist) is given, with serial LH/FSH measured over 1–2 hours — a robust, pubertal-range LH rise confirms central precocious puberty; a blunted, prepubertal-pattern response supports peripheral precocious puberty.

Neuroimaging and Therapy

MRI brain (hypothalamic-pituitary region) is indicated for confirmed central precocious puberty, to identify/exclude an underlying structural CNS lesion — particularly important in boys (central PP more likely to reflect an identifiable structural cause vs girls, where idiopathic predominates) and any child with additional neurological signs.

Central PP therapy: GnRH agonist therapy (e.g., leuprolide depot) — continuous, non-pulsatile GnRH agonist exposure paradoxically downregulates/desensitizes pituitary GnRH receptors, suppressing gonadotropin secretion and halting pubertal progression, both delaying further advancement and preserving/improving final adult height potential by slowing premature bone age advancement.

Peripheral PP therapy: directed at the specific identified cause (surgical management of a tumor, glucocorticoid replacement for CAH, specific pharmacological blockade of excess sex steroid pathways in McCune-Albright) — not GnRH agonist therapy, which would be ineffective since the HPG axis is not the driving abnormality.

Definition

Cerebral Palsy (CP) is a group of permanent disorders of movement and posture development, causing activity limitation, attributed to non-progressive disturbances occurring in the developing fetal or infant brain — the non-progressive nature of the underlying brain injury is a central, defining feature (distinguishing CP from progressive neurodegenerative conditions), even though the clinical manifestations can evolve over time (particularly evolving contractures/orthopedic complications): the underlying brain lesion itself does not progress, though the clinical picture is not entirely static.

SCPE / Topographical Classification

By motor type:

• Spastic CP (most common) — increased tone/hypertonia, hyperreflexia, “clasp-knife” resistance quality — upper motor neuron/pyramidal tract injury
• Dyskinetic CP — dystonic (fluctuating tone, sustained abnormal postures) or choreoathetotic (irregular, involuntary movements) subtypes — basal ganglia injury, classically severe kernicterus (Q4) or basal-ganglia-predominant HIE
• Ataxic CP — impaired coordination/balance — cerebellar injury
• Mixed CP — combines features of more than one type, common in more severely affected children

By topographical distribution (spastic CP): Monoplegia (single limb, rare isolated), Hemiplegia (one side, arm typically more affected), Diplegia (both legs predominantly, lesser/milder upper limb involvement — classically preterm birth and periventricular leukomalacia, given the corticospinal fiber location for lower limbs within the vulnerable periventricular white matter), Quadriplegia (all four limbs significantly affected — more severe, extensive injury, frequent additional comorbidities).

Gross Motor Function Classification System (GMFCS)

GMFCS level generally remains relatively stable through childhood, making it a useful longitudinal prognostic anchor, widely used clinically and in research.

Spasticity Management

• Botulinum toxin — targeted, localized reduction of tone in specific muscle groups, particularly for focal spasticity (e.g., calf spasticity/equinus gait); temporary effect (~3–6 months), requiring repeated injections; often used to create a “window” for more effective physiotherapy/bracing
• Intrathecal Baclofen — via a surgically implanted, programmable pump, providing generalized, whole-body tone reduction — for severe, generalized spasticity or mixed spastic-dystonic patterns not adequately managed with oral medications/local botulinum toxin, achieving therapeutic effect at lower doses with reduced systemic side-effect burden vs equivalent oral baclofen
• Oral antispasmodics (baclofen, diazepam, tizanidine) — generalized, less potent, more side-effect-limited (particularly sedation), often an initial step before escalation
• Selective Dorsal Rhizotomy — surgical, permanent sectioning of specific hyperactive dorsal (sensory) spinal nerve rootlets, reducing excessive sensory input driving spasticity — particularly for carefully-selected, ambulatory children with predominantly spastic diplegic CP, aiming for durable, permanent tone reduction to improve gait mechanics

Multidisciplinary Rehabilitation

Physiotherapy (gross motor function, gait training, contracture prevention), occupational therapy (fine motor, adaptive equipment, ADLs), speech and language therapy (communication and oromotor dysphagia/feeding difficulties, given aspiration/nutritional risks), orthopedic surveillance (hip surveillance programs are standard, given significant progressive hip subluxation/dislocation risk requiring regular scheduled radiographic monitoring even without symptoms), nutritional support, orthotic/assistive devices, and ongoing management of associated comorbidities (epilepsy, intellectual disability, visual/hearing impairment) and behavioral/psychological support for child and family.

The HEADSSS Framework

HEADSSS is a structured psychosocial interview framework specifically for adolescent clinical encounters, providing a systematic approach to exploring domains of adolescent life and risk that might otherwise be missed — the mnemonic guides a deliberately structured progression, typically moving from less sensitive toward more sensitive topics as rapport is established:

• H — Home: family relationships, living situation, family conflict/stability
• E — Education/Employment: school performance, attendance, future/career plans, peer relationships, bullying
• A — Activities: peer relationships, hobbies, extracurricular involvement, media/screen time, exercise
• D — Drugs: substance use — tobacco, alcohol, other drugs (self and peer/household)
• S — Sexuality: sexual activity, sexual orientation/gender identity, contraception, STI risk/prevention
• S — Suicide/Depression: mood, mental health screening, self-harm or suicidal ideation
• S — Safety: exposure to violence (including dating violence), access to weapons, seatbelt/helmet use, other safety behaviors

A structured, systematic approach is particularly valuable given evidence that adolescents are more likely to disclose sensitive information within a structured, non-judgmental, comprehensive framework, and that many significant risks (mental health, substance use, sexual health) are otherwise commonly missed.

Common Adolescent Health Issues

Substance abuse (screening and early identification, given adolescence as a high-risk period for initiation), eating disorders (anorexia nervosa, bulimia nervosa — adolescence represents peak onset), and mental health concerns (depression, anxiety, suicide risk — a major, increasingly recognized component of adolescent morbidity, with the “Suicide/Depression” domain specifically designed to screen for this often under-disclosed risk).

Legal Aspects — POCSO

The Protection of Children from Sexual Offences (POCSO) Act, India's specific legal framework addressing child sexual abuse, carries direct clinical relevance — healthcare providers have a legal, mandatory reporting obligation under POCSO when there is reasonable suspicion of child sexual abuse. Awareness of this framework, its reporting requirements, and its implications for confidentiality (an inherently complex tension — confidentiality is generally important for encouraging honest disclosure, but has clear, legally-mandated limits in suspected abuse) is essential for medico-legally appropriate adolescent health practice in the Indian context, intersecting directly with the sexuality/safety domains explored through HEADSSS.

Definition

Delayed puberty is generally defined as absence of any pubertal onset signs by age 13 in girls (no breast development) or age 14 in boys (no testicular enlargement) — significantly beyond the typical population range, warranting evaluation.

Causes

Constitutional Delay of Growth and Puberty (CDGP) — the most common cause overall, particularly in boys, a normal variant of maturational tempo (often with a family history of similarly delayed puberty in a parent) — ultimately puberty proceeds normally, simply later, with normal adult stature and reproductive function achieved.

Hypogonadotropic Hypogonadism — a primary hypothalamic-pituitary defect, inadequate GnRH/gonadotropin secretion failing to adequately stimulate intrinsically normal gonads. Causes: functional (chronic systemic illness, significant malnutrition/underweight state including from disordered eating or excessive athletic training, hypothyroidism), and structural/organic (CNS tumors, particularly craniopharyngioma, congenital GnRH deficiency such as Kallmann syndrome — notably associated with anosmia/hyposmia given the shared embryological migratory pathway of GnRH-secreting and olfactory neurons, an important, classic association).

Hypergonadotropic Hypogonadism — primary gonadal failure, with the hypothalamic-pituitary axis compensatorily elevating gonadotropin secretion to stimulate non-responsive/failing gonads. Causes: chromosomal/genetic (Turner syndrome in girls, Klinefelter syndrome in boys), and acquired gonadal damage (prior chemotherapy/radiation, autoimmune gonadal failure, direct gonadal injury).

Evaluation

History/examination (chronic systemic disease signs, dysmorphic features, specific smell testing given the Kallmann association), bone age assessment (typically delayed in CDGP), and — the central distinguishing test — basal LH/FSH levels, distinguishing hypogonadotropic (low/inappropriately normal LH/FSH despite absent puberty) from hypergonadotropic (elevated LH/FSH, compensatory response to gonadal failure) patterns — guiding further investigation (karyotype for suspected Turner/Klinefelter, pituitary/hypothalamic MRI for suspected structural hypogonadotropic causes), with careful observation/monitoring in cases of genuine diagnostic uncertainty between CDGP and organic hypogonadotropic hypogonadism.

Hormone Replacement Protocols

For confirmed hypogonadism requiring treatment, low-dose sex steroid replacement (testosterone in boys; estrogen — subsequently combined with progesterone once breakthrough bleeding/endometrial considerations arise — in girls) is initiated at a carefully titrated low starting dose, gradually increased over an extended period to mimic the normal, gradual tempo of physiological puberty (rather than abruptly inducing full adult-level exposure) — achieving age-appropriate secondary sexual characteristic development, appropriate bone mineralization, and preservation of final adult height potential by avoiding premature growth plate fusion from too-rapid, high-dose exposure.

Denver Developmental Screening Test (DDST-II)

A widely internationally recognized, standardized screening tool covering the same four core developmental domains discussed in Q70, assessed via direct observed testing combined with caregiver report, for children birth to 6 years — identifying children whose development falls significantly outside the expected range, warranting further diagnostic evaluation. DDST-II is explicitly designed and validated as a screening tool, not a diagnostic instrument — an abnormal result indicates the need for further, more definitive assessment, not itself a diagnosis.

Trivandrum Developmental Screening Chart (TDSC)

An India-specific tool, developed and validated within the Indian pediatric population, designed to be simple, rapid, and practically feasible even for primary-level healthcare workers in resource-limited/community settings (rather than requiring specialized developmental assessment training) — covering birth to 2-year age range with a streamlined item set, prioritizing practical, widespread applicability within India's community/primary healthcare delivery context over comprehensiveness.

Ages & Stages Questionnaires (ASQ)

A parent-completed, questionnaire-based tool covering a broad developmental domain structure across a wide age range (1 month to 5.5 years, using age-specific questionnaires), designed for parents/caregivers to complete themselves (rather than requiring direct in-person structured testing) — offering reduced provider time burden and cost, particularly suitable for efficient screening across large primary care populations, though relying on adequate parental literacy/engagement.

Comparative Summary

Each tool reflects a distinct balance of comprehensiveness, resource requirement, and practical applicability: DDST-II — well-established, internationally validated, comprehensive direct-assessment, requiring dedicated provider time and training; TDSC — streamlined, India-specific, optimized for practical, widespread use at the community health worker level; ASQ — efficient, parent-completed, minimizing provider time while maintaining broad domain coverage. Examiners often frame comparative questions around this trade-off between comprehensiveness/validation robustness versus practical, resource-appropriate feasibility.

Microcephaly

Defined as occipitofrontal head circumference >2 SD below the mean for age/sex (severe microcephaly >3 SD), reflecting either a primary (genetic/developmental) defect in brain growth or a secondary process disrupting otherwise normal brain growth potential.

• Genetic causes: primary microcephaly syndromes (mutations in genes governing neuronal proliferation/migration), and microcephaly as a feature within numerous broader genetic/chromosomal syndromes (including Down syndrome)
• Intrauterine/congenital causes: congenital infections (TORCH) — congenital CMV and, of major contemporary significance, congenital Zika virus infection (a relatively recently recognized, prominent cause following the significant Zika outbreak-associated microcephaly cluster); intrauterine teratogen exposure (alcohol — fetal alcohol syndrome, certain medications); significant IUGR from placental insufficiency
• Structural/acquired causes: significant perinatal hypoxic-ischemic brain injury, severe neonatal hypoglycemia, and other significant early postnatal brain insults

Macrocephaly

Defined as head circumference >2 SD above the mean, spanning entirely benign familial/genetic variation (requiring correlation with parental head circumference — a large head in an otherwise well, developmentally normal child with a similarly large-headed parent is generally reassuring) through genuinely pathological causes:

• Hydrocephalus — excess CSF accumulation, obstructive or communicating (see Q21)
• Megalencephaly — genuine, primary brain parenchyma enlargement (not excess CSF), isolated/benign familial or as a feature of specific genetic/metabolic syndromes (overgrowth syndromes, some neurocutaneous syndromes)
• Subdural hematoma/effusion — important to specifically consider, particularly in infants, given the critical differential of potential non-accidental injury/abusive head trauma
• Metabolic/storage disorders — certain inborn errors (leukodystrophies, lysosomal storage disorders) can present with macrocephaly as a prominent, sometimes early, feature

Diagnostic Imaging Recommendations

Cranial ultrasound — practical, radiation-free first-line option for young infants with an open anterior fontanelle, providing reasonable initial structural assessment without sedation. MRI brain — preferred, more detailed modality once the fontanelle has closed (or where ultrasound is abnormal/inconclusive), generally preferred over CT given avoidance of ionizing radiation, with CT reserved for specific situations (rapid acquisition without sedation in acute settings, or superior calcification detection).

Temper Tantrums

A normal, developmentally expected phenomenon, particularly common in toddlers (roughly 1–4 years), reflecting the mismatch between emerging desire for independence and still-limited emotional self-regulation/verbal communication capacity. Management: consistent, calm parental response (avoiding both excessive punitive reaction and reinforcing the tantrum through excessive attention/capitulation), ensuring physical safety, and structured behavioral strategies (consistent routines, clear limits, positive reinforcement). Unusually severe, frequent, prolonged tantrums, or persistence beyond the typical age range, warrant evaluation for a possible underlying contributing factor.

Breath-Holding Spells

A distinctive, involuntary phenomenon in young children (typically 6 months–5 years):

• Cyanotic — triggered by anger, frustration, or pain; vigorous crying followed by expiratory breath-holding, cyanosis, and, in severe episodes, brief loss of consciousness (occasionally with brief clonic movements, causing potential confusion with seizure)
• Pallid — triggered by sudden minor injury or fright, with a reflex vagally-mediated, cardioinhibitory mechanism (transient bradycardia/asystole, related to the reflex anoxic seizure/vasovagal mechanism) producing sudden pallor and loss of consciousness, often minimal preceding crying

Both types are generally benign, self-limiting, and outgrown by school age. Management: parental reassurance/education (recognizing the involuntary nature, counseling against reinforcing perceived voluntary control). Iron deficiency anemia has a recognized association with spell frequency/severity, and iron supplementation reduces frequency in some cases — a specific, actionable consideration.

Pica

Persistent eating of non-nutritive, non-food substances (dirt, paper, paint chips) beyond the developmentally normal mouthing exploration of infancy — associated with iron deficiency and other micronutrient deficiencies, developmental delay/intellectual disability, and significant psychosocial stressors. Management: address any identified nutritional deficiency, behavioral intervention/environmental modification, and specific screening/monitoring for complications (lead poisoning from paint chips, intestinal parasitic infection from soil ingestion, or mechanical bowel obstruction from indigestible material such as trichobezoar with trichophagia).

Enuresis

Involuntary urination beyond the developmentally expected age of bladder control (generally >age 5), classified as primary (never achieved sustained dryness) or secondary (recurring after a previously established dry period — warranting more careful evaluation for a specific trigger, including psychosocial stressors, UTI, or, less commonly, diabetes mellitus/insipidus). Management for primary nocturnal enuresis begins with behavioral/motivational approaches (fluid restriction timing, scheduled voiding, positive reinforcement, enuresis alarm systems — the most effective, evidence-based first-line behavioral intervention, working via conditioning to train waking in response to bladder fullness), with pharmacological options (desmopressin, or less commonly imipramine given a less favorable side-effect profile) reserved for cases not adequately responding to behavioral measures alone or specific situational needs.

Definition — A Dual (IQ Plus Adaptive Function) Framework

Both AAIDD and DSM-5 frameworks define Intellectual Disability based on deficits in both intellectual functioning (typically IQ ≥~2 SD below mean, roughly <70) AND deficits in adaptive functioning (conceptual, social, and practical skill domains — applying cognitive abilities to everyday functional tasks/independence), with onset during the developmental period (before age 18). A critical, frequently-tested point: DSM-5 severity classification is now based primarily on adaptive functioning level, not the specific numerical IQ score — reflecting the recognition that real-world support need/functional impairment is more meaningfully captured by adaptive functioning than IQ alone.

AAIDD/DSM-5 Severity Classification (Based on Adaptive Functioning)

IQ Testing Tools

Standardized, age-appropriate cognitive assessment tools including Wechsler scales (WPPSI — preschool, WISC — school age, WAIS — adolescents/adults) and Stanford-Binet Intelligence Scales — with formal, standardized adaptive functioning assessment (e.g., Vineland Adaptive Behavior Scales) performed alongside, reflecting the dual-domain diagnostic requirement.

Genetic Counseling

Given the substantial proportion of ID cases with an identifiable underlying genetic etiology (increasingly detected with modern genetic testing, Q67 and Q194), genetic counseling is an essential component of comprehensive management — providing information on the specific identified (or still-undiagnosed) etiology, associated prognosis/expected clinical course, recurrence risk for future pregnancies (varying substantially by underlying mechanism — sporadic versus inherited, and specific inheritance pattern), and guidance regarding reproductive options and family planning — should be offered as a standard, integral part of the care pathway for any child with confirmed or strongly suspected genetic ID.